249 results
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
20 Mar 24
RepliCel announces a Letter of Intent for Asset Purchase Agreement
4:38pm
of RepliCel. Collectively, the potential impacts of this economic environment pose risks that are currently indescribable and immeasurable. No assurance can
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
there is a shortfall from operations. While the Company is continuing its best efforts to achieve the above plans, there is no assurance that any such activity … . There is no assurance that potential equity financing opportunities will be available to meet these obligations.
The following table sets out
6-K
EX-99.4
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
to the establishment and maintenance of
i) controls and other procedures designed to provide reasonable assurance that information required … , summarized and reported within the time periods specified in securities legislation; and
ii) a process to provide reasonable assurance regarding
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
may make it difficult to raise funds by private placements of shares. There is no assurance that the Company will be successful with its financing … , there is no assurance that any such activity will generate funds for operations.
We anticipate requiring additional funds to proceed with our current plan
6-K
EX-99.3
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
assurance that information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted under … to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes
6-K
EX-99.1
36gylg
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
6-K
EX-99.3
sp5nztkezpcul193k0
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
6-K
EX-99.4
gugi385 b66v1v56
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
6-K
EX-99.2
vif0 noyiuatuh6r3
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
6-K
EX-99.1
pr22s6t7ju
19 Oct 23
Current report (foreign)
1:45pm
6-K
EX-99.1
jwzszrk
4 Oct 23
RepliCel Provides Default Status Update and Announces Shareholder Approval of Equity Incentive Plan
2:23pm
6-K
EX-99.2
ap8gdq
13 Sep 23
RepliCel Announces DermaPrecise™ Development Milestone, Updates Arbitration Proceedings
5:32pm
6-K
EX-99.2
03afli6e r775
30 Aug 23
Notice of Annual General and Special Meeting of Shareholders
5:15pm
6-K
EX-99.3
vh27f8ncmppq5 o9e
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
6-K
EX-99.2
j44x7aff
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
6-K
EX-99.1
11gi5wyhpfgo
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
6-K
EX-99.4
x88df
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm